bioAffinity Technologies Welcomes New Board Members
SAN ANTONIO, Nov. 29, 2017 (GLOBE NEWSWIRE) -- bioAffinity Technologies, a privately held cancer diagnostics and therapeutics company, today announced the appointments of Stephen Squinto, Ph.D., and Gary Rubin, CPA, to its Board of Directors.
Dr. Squinto is a Venture Partner with OrbiMed Healthcare Fund Management. He previously co-founded Alexion Pharmaceuticals, Inc., a global biopharmaceutical company focused on the development and commercialization of breakthrough therapies for patients with rare and ultra-rare diseases. As Executive Vice President and Chief Global Operations Officer, Dr. Squinto helped build Alexion into a company currently valued at $25 billion. Prior to 2013, he served as head of Alexion’s Global Research and Development.
“Dr. Squinto is both a scientist and a business leader whose expertise and strategic leadership will be invaluable as we continue to advance our diagnostic tests and therapeutics for the early detection and successful treatment of multiple cancers,” said Steve Girgenti, Chairman of the bioAffinity Board of Directors. “As our scientific team continues to push our innovative CyPath® Lung diagnostic toward commercialization, bioAffinity will benefit from Dr. Squinto’s 25-plus years of experience in the biotechnology industry.”
Prior to his work at Alexion, Dr. Squinto held various positions at Regeneron Pharmaceuticals, Inc., and served in a joint academic position at the Tulane University and Louisiana State University Schools of Medicine. He is a recipient of numerous honors and awards from academic and professional organizations for his scientific work. Dr. Squinto earned his B.A. in Chemistry and Ph.D. in Biochemistry and Biophysics from Loyola University of Chicago.
Gary Rubin, a Certified Public Accountant, has been involved for more than 20 years in the investment management industry, including hedge funds, private equity and investment banking. He currently serves as a Managing Member of Masters Research Partners, LLC, a fund of hedge funds that he co-founded in October 2000. He began his career with Deloitte & Touche and later served as Managing Partner at Schissel, Rubin & Lehman, a New York-based Certified Public Accounting firm.
“Gary Rubin’s skill, experience and knowledge of financial transactions and investment opportunities are valuable additions to our Board as we commercialize our technologies and look to build strategic alliances with partners in the diagnostic and therapeutic fields,” Mr. Girgenti said. “His accounting expertise also provides an important perspective on day-to-day operations, strengthening our Company as we enter the biotech market.”
In addition to his position with Masters Research Partners, Mr. Rubin is active in his family’s foundation and numerous charities. He presently serves on the Board of Boca Raton Regional Hospital Foundation and the Finance Committee of the Levitz Jewish Community Center. Mr. Rubin earned a B.S. cum laude from the State University of New York, Buffalo.
About bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. (www.bioaffinitytech.com) is a privately held development-stage company that develops proprietary in-vitro diagnostic tests and targeted cancer therapeutics using breakthrough technology that preferentially targets cancer cells. The Company’s initial product is CyPath® Lung, a diagnostic assay for the detection of early-stage lung cancer.
Contact: Maria Zannes, 505.400.9747
Released November 29, 2017